Post-heart transplant complications

Critical Care Clinics

Volumn 30, Issue 3, 2014, Pages 629-637

  Birati, Edo Y ^a   Rame, J Eduardo ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Complications; Heart transplant; Immunosuppression; Rejection

Indexed keywords

VALGANCICLOVIR; WARFARIN; IMMUNOSUPPRESSIVE AGENTS;

CARDIAC GRAFT REJECTION; CORONARY ARTERY DILATATION; GRAFT FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HEART RIGHT VENTRICLE FUNCTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM SURVIVAL; MORBIDITY; MORTALITY; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; SEPSIS; VALVULAR HEART DISEASE; ADVERSE EFFECTS; HEART DISEASES; HUMANS; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; SURVIVAL RATE;

HEART DISEASES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; SURVIVAL RATE;

EID: 84903615975     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2014.03.005     Document Type: Review

References (38)

1. United Health Group. Transplant review guidelines. 2013.
2. Lindenfeld J., Miller G.G., Shakar S.F., et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation 2004, 110(25):3858-3865.
3. Acker M.A., Jessup M. Surgical management of heart failure. Braunwald's heart disease: a textbook of cardiovascular medicine 2012, 601-616. Elsevier Saunders, St. Louis (MO). 9th edition. R.O. Bonow, D.L. Mann, D.P. Zipes (Eds.).
4. Singh N., Pirsch J., Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando) 2009, 23(1):34-46.
5. Stewart S., Winters G.L., Fishbein M.C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005, 24(11):1710-1720.
6. Jessup M., Brozena S. State-of-the-art strategies for immunosuppression. Curr Opin Organ Transplant 2007, 12:536.
7. Costanzo M.R., Dipchand A., Starling R., et al. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010, 29(8):914-956.
8. Schmauss D., Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008, 117(16):2131-2141.
9. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report: 2006. J Heart Lung Transplant 2006, 25:869-879.
10. Weis M., von Scheidt W. Coronary artery disease in the transplanted heart. Annu Rev Med 2000, 51:81-100.
11. Stork S., Behr T.M., Birk M., et al. Assessment of cardiac allograft vasculopathy late after heart transplantation: when is coronary angiography necessary?. J Heart Lung Transplant 2006, 25:1103-1108.
12. Ciliberto G.R., Massa D., Mangiavacchi M., et al. High-dose dipyridamole echocardiography test in coronary artery disease after heart transplantation. Eur Heart J 1993, 14:48-52.
13. Spes C.H., Mudra H., Schnaack S., et al. Dobutamine stress echocardiography for noninvasive diagnosis of cardiac allograft vasculopathy a comparison with angiography and intravascular ultrasound. Am J Cardiol 1996, 78:168-174.
14. Carlsen J., Toft J.C., Mortensen S.A., et al. Myocardial perfusion scintigraphy as a screening method for significant coronary artery stenosis in cardiac transplant recipients. J Heart Lung Transplant 2000, 19:873-878.
15. Sigurdsson G., Carrascosa P., Yamani M.H., et al. Detection of transplant coronary artery disease using multidetector computed tomography with adaptative multisegment reconstruction. J Am Coll Cardiol 2006, 48:772-778.
16. Wenke K., Meiser B., Thiery J., et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003, 107:93-97.
17. Steinhauff S., Pehlivanli S., Bakovic-Alt R., et al. Beneficial effects of quinaprilat on coronary vasomotor function, endothelial oxidative stress, and endothelin activation after human heart transplantation. Transplantation 2004, 77:1859-1865.
18. Bae J.H., Rihal C.S., Edwards B.S., et al. Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. Transplantation 2006, 82:1108-1111.
19. Schroeder J.S., Gao S.Z., Alderman E.L., et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 1993, 328:164-170.
20. Mancini D., Pinney S., Burkhoff D., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003, 108:48-53.
21. Streblow D.N., Orloff S.L., Nelson J.A. Acceleration of allograft failure by cytomegalovirus. Curr Opin Immunol 2007, 19:577-582.
22. Valantine H.A. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma.". Transplantation 2003, 76:891-899.
23. Fearon W.F., Potena L., Hirohata A., et al. Changes in coronary arterial dimensions early after cardiac transplantation. Transplantation 2007, 83:700-705.
24. Musci M., Loebe M., Wellnhofer E., et al. Coronary angioplasty, bypass surgery, and retransplantation in cardiac transplant patients with graft coronary disease. Thorac Cardiovasc Surg 1998, 46:268-274.
25. Leeman M., Van C.M., Vachiery J.L., et al. Determinants of right ventricular failure after heart transplantation. Acta Cardiol 1996, 51(5):441-449.
26. Sethi G.K., Lanauze P., Rosado L.J., et al. Clinical significance of weight difference between donor and recipient in heart transplantation. J Thorac Cardiovasc Surg 1993, 106(3):444-448.
27. Segovia J., Pulpon L.A., Sanmartin M., et al. Primary graft failure in heart transplantation: a multivariate analysis. Transplant Proc 1998, 30(5):1932.
28. Marasco S.F., Esmore D.S., Negri J., et al. Early institution of mechanical support improves outcomes in primary cardiac allograft failure. J Heart Lung Transplant 2005, 24(12):2037-2042.
29. Stobierska-Dzierzek B., Awad H., Michler R.E. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 2001, 38(4):923-931.
30. Kieler-Jensen N., Lundin S., Ricksten S.E. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside. J Heart Lung Transplant 1995, 14(3):436-443.
31. Wong R.C., Abrahams Z., Hanna M., et al. Tricuspid regurgitation after cardiac transplantation: an old problem revisited. J Heart Lung Transplant 2008, 27(3):247-252.
32. Rees A.P., Milani R.V., Lavie C.J., et al. Valvular regurgitation and right-sided cardiac pressures in heart transplant recipients by complete Doppler and color flow evaluation. Chest 1993, 104(1):82-87.
33. Argenziano M., Choudhri A.F., Oz M.C., et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997, 96(Suppl 9). II-286-90.
34. Leyh R.G., Kofidis T., Struber M., et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?. J Thorac Cardiovasc Surg 2003, 125(6):1426-1431.
35. Prendergast T.W., Furukawa S., Beyer A.J., et al. Defining the role of aprotinin in heart transplantation. Ann Thorac Surg 1996, 62(3):670-674.
36. Mangano D.T., Tudor I.C., Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006, 354(4):353-365.
37. Karkouti K., Beattie W.S., Dattilo K.M., et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006, 46(3):327-338.
38. Fremes S.E., Wong B.I., Lee E., et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994, 58(6):1580-1588.